HRS9531 injection

DRUG11 trials

Sponsors

Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions

Diabetes Mellitus, Type 2ObesityOverweight or ObesityOverweight/ObesityType 2 DiabetesWeight Management

Phase 1

Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects

CompletedNCT06654960

Fujian Shengdi Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2024-11-05End: 2024-12-26Updated: 2025-01-07

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

RecruitingNCT06762600

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2025-01-16End: 2025-12-31Target: 103Updated: 2025-04-30

The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution

CompletedNCT06792955

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight/Obesity

Start: 2025-02-11End: 2025-06-06Updated: 2025-06-12

Phase 2

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

CompletedNCT05881837

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2023-06-13End: 2024-10-13Updated: 2025-04-30

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

CompletedNCT05966272

Fujian Shengdi Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2023-08-12End: 2024-09-24Updated: 2025-05-07

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2023-10-31End: 2024-09-30Target: 60Updated: 2023-09-26

A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea

Not yet recruitingNCT06565871

Fujian Shengdi Pharmaceutical Co., Ltd.Weight Management

Start: 2024-08-31End: 2025-12-31Target: 108Updated: 2024-08-22

Phase 3

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

CompletedNCT06396429

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2024-05-13End: 2025-07-07Updated: 2025-07-11

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Active, not recruitingNCT06649344

Fujian Shengdi Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2024-10-31End: 2026-09-30Updated: 2025-06-12

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

Active, not recruitingNCT06650007

Fujian Shengdi Pharmaceutical Co., Ltd.Diabetes Mellitus, Type 2

Start: 2024-11-08End: 2026-07-31Updated: 2025-06-12

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Active, not recruitingNCT07285902

Fujian Shengdi Pharmaceutical Co., Ltd.Obesity

Start: 2025-12-25End: 2027-03-01Updated: 2026-02-27